These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Management of hypertrophic cardiomyopathy in children. Seggewiss H; Rigopoulos A Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624 [TBL] [Abstract][Full Text] [Related]
6. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment. Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218 [TBL] [Abstract][Full Text] [Related]
7. Sudden death and hypertrophic cardiomyopathy: a review. Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263 [TBL] [Abstract][Full Text] [Related]
8. [Ambulatory ECG in cardiomyopathies]. Mestroni L; Miani D; Neri R; Di Lenarda A; Camerini F G Ital Cardiol; 1987 Dec; 17(12):1139-44. PubMed ID: 3503812 [TBL] [Abstract][Full Text] [Related]
9. Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy. Mercereau D; Kubac G; Klinke WP Can J Cardiol; 1989 Mar; 5(2):77-80. PubMed ID: 2706577 [TBL] [Abstract][Full Text] [Related]
10. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Ostman-Smith I Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015 [TBL] [Abstract][Full Text] [Related]
11. Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction. McAreavey D; Fananapazir L Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 1):1642-5. PubMed ID: 1279528 [TBL] [Abstract][Full Text] [Related]
12. [Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm and sustained ventricular tachycardia: a case report]. Kono K; Higashi T; Hara K; Mori S; Ito I; Shinbo G; Anzai R; Yagi H; Tamano K; Horinaka S; Matsuoka H J Cardiol; 2001 Dec; 38(6):343-9. PubMed ID: 11806092 [TBL] [Abstract][Full Text] [Related]
13. [Hypertrophic cardiomyopathy with midventricular obstruction of the left ventricle (MVO)--case report]. Pizoń T; Rajzer M; Wojciechowska W; Jastrzebski M; Olszanecka A; Rojek M; Jurczyszyn A; Czarnecka D Przegl Lek; 2015; 72(5):271-5. PubMed ID: 26817332 [TBL] [Abstract][Full Text] [Related]
14. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Fananapazir L; Leon MB; Bonow RO; Tracy CM; Cannon RO; Epstein SE Am J Cardiol; 1991 Jan; 67(2):169-74. PubMed ID: 1987718 [TBL] [Abstract][Full Text] [Related]
16. Arrhythmia and hypertrophic cardiomyopathy. Shakespeare CF; Keeling PJ; Slade AK; McKenna WJ Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():31-6. PubMed ID: 1307192 [TBL] [Abstract][Full Text] [Related]
17. [Sudden death and obstructive hypertrophic cardiomyopathy]. Baille N Ann Cardiol Angeiol (Paris); 1985 Mar; 34(3):155-60. PubMed ID: 3890678 [TBL] [Abstract][Full Text] [Related]
18. Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone. Nanda S; Levin V; Martinez MW Minerva Cardioangiol; 2012 Dec; 60(6):637-42. PubMed ID: 23147440 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy]. Sadoul N; de Chillou C; Aliot E; McKenna WJ Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160 [TBL] [Abstract][Full Text] [Related]